{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-101410","form_type":"8-K","ticker":"TTRX","cik":"0002023016","company_name":"Turn Therapeutics Inc.","filed_at":"2025-10-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.348294+00:00","generated_at":"2026-05-17T02:51:44.561238+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Turn Therapeutics updates on GX-03 phase 2 eczema trial: 25% enrolled, topline 2026; $85M GEM facility","bullets":["Phase 2 trial of GX-03 (topical IL-36/IL-31 inhibitor) for moderate-severe eczema: ~25% of targeted sample completed, no safety concerns; topline results expected in 2026.","Company completed dilution-sparing direct listing with $85M GEM Global Yield on-demand financing vehicle to reduce reliance on future equity offerings.","Intranasal vaccine initiative advancing; in-vivo studies scheduled to commence in Q4 2025.","Shareholder webinar held today, October 22, 2025 at 2:00 PM ET to review milestones and capital strategy."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-101410","json":"https://secwatch.observer/filing/0001104659-25-101410.json","markdown":"https://secwatch.observer/filing/0001104659-25-101410.md","text":"https://secwatch.observer/filing/0001104659-25-101410.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2023016/000110465925101410/0001104659-25-101410-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2023016/000110465925101410/tm2529242d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T02:51:44.561238+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}